Wanjia Group Holdings Ltd. has released its annual financial results for the year ended 31 March 2025. The Group reported a total revenue of approximately HK$161.693 million, marking a decrease of around 10.71% compared to the previous year's revenue of approximately HK$181.092 million. The decline was attributed primarily to the pharmaceutical wholesale and distribution business, which saw a slight revenue drop of approximately 2.03% to HK$50.491 million from HK$51.536 million in 2024. The Group recorded a loss from operations of HK$4.089 million, which is a significant improvement from the previous year's loss of HK$39.438 million. The finance costs also decreased to HK$1.403 million from HK$1.711 million in 2024. Consequently, the loss before taxation narrowed to HK$5.492 million, down from HK$41.149 million in the previous year. The Board has decided not to recommend the payment of a final dividend for the year ended 31 March 2025, consistent with the prior year. No specific outlook or guidance for the upcoming year has been provided in the report.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.